Abstract:
Compounds, or pharmaceutically acceptable salts and esters thereof, of formulas: (I); (II); (III); or (IV); wherein A, B, D and E, R , R , and Z specifically defined, having antibacterial activity, pharmaceutical compositions containing said compounds, treatment of bacterial infections with such compositions, and processes for the preparation of the compounds.
Abstract:
Novel antibacterial compounds are disclosed having formula (I) as well as pharmaceutically acceptable salts, esters, amide and prodrugs thereof, wherein R1 is selected from the group consisting of (a) lower alkyl, (b) halo(lower alkyl), (c) lower alkyl(alkynyl), (d) lower cycloalkyl, (e) lower alkylamino, (f) nitrogen-containing aromatic heterocycle, (g) bicyclic alkyl and (h) phenyl; R2 is selected from the group consisting of hydrogen, lower alkyl, a pharmaceutically acceptable cation, and a prodrug ester group; R?3 and R4¿ are independently selected from the group consisting of hydrogen, halogen, amino, and lower alkyl; R5 is either a nitrogen-containing heterocycle or a nitrogen-containing spiro-bicyclic-heterocycle; and A is N or C-R6, wherein R6 is selected from the group consisting of hydrogen, halogen, lower alkyl, and lower alkoxy, or R?1 and R6¿ taken together with the atoms to which they are attached form a 6-membered ring which may contain an oxygen or sulfur atom and which may be substituted with lower alkyl; as well as pharmaceutical compositions comprising such novel compounds and the therapeutic use thereof.
Abstract:
Novel 3-descladinose-2,3-anhydroerythromycin compounds and pharmaceutically acceptable salts and esters thereof having antibacterial activity selected from the group consisting of: (a) (I), (b) (II), (c) (III), and (d) (IV), pharmaceutical compositions comprising a therapeutically effective amount of a compound of formulas (I)-(IV) of the invention in combination with a pharmaceutically acceptable carrier, as well as a method for treating bacterial infections by administering to a mammal a pharmaceutical composition containing a therapeutically-effective amount of a compound of formulas (I)-(IV) of the invention.
Abstract:
Quinobenzoxazine, quinobenzothiazines, and pyrido-acridine derivatives of formula (I) as well as the pharmaceutically acceptable salts, esters, amides and prodrugs thereof are disclosed, wherein R is hydrogen or acarboxy-protecting group, R and R are substituents, A is oxygen, sulfur, or carbon, Z is a halogen or a nitrogen-containing group, X is hydrogen, halogen or alkyl, and W is hydrogen, alkyl, amino or halogen. The compounds have potent antineoplastic activity.
Abstract:
Antimicrobial compounds having formula (II), (III), (IV), (V), (VI), (VII), (VIII) and (IX); as well as the pharmaceutically acceptable salts, esters and prodrugs thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administration of such compounds; and processes for the preparation of the compounds.
Abstract:
A compound selected from groups (I), (II), and (III), wherein A, B, V, W, X and R are specifically defined; pharmaceutical compositions thereof; a method of treating or preventing bacterial infections by administering therapeutically effective pharmaceutical compositions thereof; and a process for the preparation thereof.
Abstract:
Benzo[5.6]pyrano[2.3.4-ij]quinolizine and benzo[5.6]thiopyrano[2.3.4-ij]quinolizine compounds having formula (I), wherein A is sulfur or oxygen; R is selected from the group consisting of hydroxy, protected-hydroxy, C1-C6-alkoxy, halo, amino, C1-C6-alkylamino, hydroxy-C1-C6-alkylamino, bicyclic nitrogen-containing heterocycle, nitrogen-containing aromatic heterocycle, and nitrogen-containing heterocycle; R is selected from the group consisting of hydrogen, halo, C1-C6-alkyl, or halo-C1-C6-alkyl; R is selected from the group consisting of hydrogen, C1-C6-alkyl or C5-C7-cycloalkyl; and R and R are independently selected from the group consisting of hydrogen, C1-C6-alkyl or C1-C6-alkoxyl, having utility as intermediates or having antibacterial or antineoplastic activity.
Abstract:
Compounds, or pharmaceutically acceptable salts and esters thereof, of formulae (I); (II); (III) or (IV) wherein A, B, D and E, R , R and Z are specifically defined, having antibacterial activity, pharmaceutical compositions containing said compounds, treatment of antibacterial infections with such compositions, and processes for the preparation of the compounds.
Abstract:
Antibacterical coumpounds having formula (I) and the pharmaceutically acceptable salts, esters and amides thereof, preferred examples of which include those coumpounds wherein R is cycloalkyl of from three to eight carbon atoms or substituted phenyl; R is selected from the group consisting of (a) halogen, (b) loweralkyl, (c) loweralkenyl, (d) cycloalkyl of from three to eight carbons, (e) cycloalkenyl of from four to eight carbons, (f) loweralkoxy, (g) aryloxy, (h) aryl(loweralkyl)oxy, (i) aryl(loweralkyl), (j) cycloalkyl(loweralkyl), (k) amino, (l) (loweralkyl)amino, (m) aryl(loweralkyl)amino, (n) hydroxy substituted (loweralkyl)amino, (o) phenyl, (p) substituted phenyl, (q) bicyclic nitrogen-containing heterocycle, (r) nitrogen-containingaromatic heterocycle, and (s) nitrogen-containing heterocycle having formula (Ia) where x is between zero and three; R is halogen; R is hydrogen, loweralkyl, a pharmaceutically acceptable cation, or a prodrug ester group; R is hydrogen, loweralkyl, halo(loweralkyl), or -NR R ; and R is loweralkyl, as wellas pharmaceutical compositions containing such compounds and the use of the same in the treatment of bacterial infections.
Abstract translation:具有式(I)的抗菌配方及其药学上可接受的盐,酯和酰胺,其优选实例包括其中R 1为3至8个碳原子的环烷基或取代的苯基的那些芳族基团; R 2选自(a)卤素,(b)低级烷基,(c)低级烯基,(d)3至8个碳的环烷基,(e)4至8个碳的环烯基,(f )低级烷氧基,(g)芳氧基,(h)芳基(低级烷基)氧基,(i)芳基(低级烷基),(j)环烷基(低级烷基),(k)氨基,(1)(低级烷基)氨基,(m) (低级烷基)氨基,(n)羟基取代的(低级烷基)氨基,(o)苯基,(p)取代的苯基,(q)双环含氮杂环,(r)含氮芳族杂环,和 具有式(Ia)的杂环,其中x在0和3之间; R 3是卤素; R 4是氢,低级烷基,药学上可接受的阳离子或前药酯基; R 5是氢,低级烷基,卤代(低级烷基)或-NR 13 R 14; R 6为低级烷基,以及含有这些化合物的药物组合物及其在治疗细菌感染中的用途。